There are a handful of ASX blue chips I'd be comfortable owning for the next decade.
Two familiar names are high on that list. But there's another business I'd put ahead of both, largely because I think investors could be underestimating how much room it has to grow.

Image source: Getty Images
Why I'd buy CBA and BHP shares
I remain a fan of Commonwealth Bank of Australia (ASX: CBA).
Its enormous customer base, leading digital banking services, and strength in deposits give it advantages that competitors have spent years trying to match.
And its latest quarterly update showed that the bank is still growing lending while maintaining a broadly stable underlying interest margin.
I'd also happily own BHP Group Ltd (ASX: BHP) shares.
Its iron ore business generates significant cash flow, while copper and the emerging potash business could become bigger earnings contributors over time.
BHP will always be exposed to commodity cycles, but I like having several ways to benefit from global demand for resources.
So why would I put another company first?
The blue chip I'd choose
My pick is ResMed Inc (ASX: RMD), the sleep health technology company.
The biggest reason I'd favour it is the extraordinary number of people who could benefit from its products but aren't receiving treatment.
According to ResMed's investor presentations, more than one billion people worldwide are estimated to have sleep apnoea.
Yet fewer than 20% of affected people in the US, and fewer than 10% elsewhere, have been diagnosed or treated. I think that's an enormous long-term opportunity.
And developments in technology could help ResMed reach more of these people.
For example, its partnership with the wearable technology company ŌURA helps users recognise potential sleep-breathing problems and connect them with sleep assessments and treatment information.
I believe growing awareness could encourage millions more people to seek diagnosis and treatment over the coming decade.
Why Ozempic might be good news
Another reason I'm positive is the growing popularity of weight-loss drugs such as Ozempic.
Initially, investors worried that these medicines could reduce demand for ResMed's sleep apnoea machines.
After all, weight loss can improve the condition for some patients.
However, there's emerging evidence suggesting these drugs could also benefit ResMed.
In its latest presentation, the company highlighted an analysis involving 3.3 million patients.
It found that patients prescribed GLP-1 drugs were more likely to begin positive airway pressure therapy and had higher replacement-supply rates than those not prescribed the drugs.
Although this doesn't prove the drugs caused greater treatment uptake, I think it challenges the assumption that their growing popularity will hurt ResMed.
And once patients begin treatment, ResMed can generate ongoing revenue from replacement masks and accessories.
The growth outlook
ResMed's ambitions are also encouraging. Management is targeting high-single-digit annual revenue growth over its five-year outlook to 2030, with earnings expected to grow faster than sales.
And its latest quarterly results suggest it's making progress. Core revenue increased 7% in constant currency, while adjusted earnings per share (EPS) rose 14%.
I believe the combination of an enormous underserved market, greater awareness, and continued product innovation could support this growth for many years.
Competition from alternative treatments and changes in healthcare reimbursement remain risks, but I'm optimistic about the company's future.
Foolish takeaway
I think CBA and BHP are excellent shares, and I'd happily own either.
However, ResMed's long-term growth opportunity looks even stronger to me.
With so many people still undiagnosed and management targeting faster earnings growth, it would be my first choice of the three today.